pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$PGENPRECIGEN, INC.

$PGEN6.8500-0.15%
Germantown, MD, USupdated 8h ago

Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 1Phase 2: 1Marketed: 1
1Phase 11Phase 21Marketed
Marketed
zopapogene imadenovec
Recurrent Respiratory Papillomatosis (Juvenile Laryngeal…
Phase 2
PRGN-2009
Anal Cancer
Phase 1
PRGN-3006
Myelodysplastic Syndrome (Preleukemia)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 4, 2026
earnings
$PGEN6.8500-0.15%
9d ago
PRECIGEN, INC. earnings
PRECIGEN, INC.
→
view all catalysts →

Active trials

  • phase2PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancerrecruitingn=24
  • phase4Zopa Retreatment and Vector Shedding in Adults With RRPrecruitingn=30
  • phase2Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosisactive not recruitingn=38
  • phase1PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDSactive not recruitingn=88
  • phase1Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Canceractive not recruitingn=71

Insider activity

source: SEC Form 4

open-market buys + sells

  • Mar 30, 26SELLKIRK RANDAL J· 2,334,420 sh @ $3.30−$7.70M↗
  • Mar 30, 26SELLKIRK RANDAL J· 1,108,998 sh @ $3.30−$3.66M↗
  • Mar 30, 26SELLKIRK RANDAL J· 426,199 sh @ $3.30−$1.41M↗
  • Mar 30, 26SELLKIRK RANDAL J· 370,847 sh @ $3.30−$1.22M↗
  • Mar 30, 26SELLKIRK RANDAL J· 168,794 sh @ $3.30−$557K↗
  • Mar 30, 26SELLKIRK RANDAL J· 152,063 sh @ $3.30−$502K↗
  • Mar 30, 26SELLKIRK RANDAL J· 50,797 sh @ $3.30−$168K↗
  • Mar 30, 26SELLKIRK RANDAL J· 50,797 sh @ $3.30−$168K↗
  • Mar 30, 26SELLKIRK RANDAL J· 47,101 sh @ $3.30−$155K↗
  • Mar 30, 26SELLKIRK RANDAL J· 38,976 sh @ $3.30−$129K↗
  • Mar 30, 26SELLKIRK RANDAL J· 23,789 sh @ $3.30−$79K↗
routine RSU / option mechanics (6)
  • Apr 20, 26grantTennant Phil · Chief Commercial Officer385,000 sh
  • Apr 20, 26grantShah Rutul R · Chief Operating Officer118,000 sh
  • Apr 20, 26grantSabzevari Helen · President and CEO1,366,000 sh
  • Apr 20, 26grantThomasian Harry Jr. · Chief Financial Officer120,000 sh
  • Apr 20, 26grantShah Rutul R · Chief Operating Officer395,000 sh
  • Apr 20, 26grantThomasian Harry Jr. · Chief Financial Officer399,000 sh
🐶 Hiring Signal
No open roles indexed yet — view PRECIGEN, INC. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$PGEN
SEC CIK
0001356090
country
US
source
sec_tickers
top tags
Oncology2Colorectal Cancer1Infectious Disease1NSCLC1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?